INTENSITY THERAPEUTICS INC (INTS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.50+3.55%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · INTS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
INTS — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition. On August 11, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and six months ended June 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by refer…
Why it matters: Management said partner talks were early but planned to continue in the second half of 2026. A signed deal could add support for the trials.
Supportive ifThe company announces a signed partnership. It names a program and states the support or funding provided.
Worry ifThe company reports no signed deal by year-end 2026 or says the partner talks have ended.
Why it matters: Cash was $9.5 million at June 30, while the company relies on ATM sales to fund trials. More cash can support study work.
Watch forThe next report shows cash above $9.5 million and new ATM proceeds, without a pause in either trial.
Also watch forCash falls below $9.5 million. The company reports less trial work or a delay due to funding.
Why it matters: The Phase 3 trial paused after 21 patients. New enrollment would show the amended study is moving again.
Supportive ifThe company confirms that at least one U.S. site has enrolled a new INVINCIBLE-3 patient.
Worry ifNo U.S. site has enrolled a new patient, or the company reports another enrollment delay.
Why it matters: Early results showed 71% pCR with INT230-6 and 42% with standard care. More patients can test whether that gap lasts.
Supportive ifA later update shows the INT230-6 group has a higher pCR rate than the standard-care group, with more than seven patients in each group.
Worry ifA later update shows the INT230-6 group's pCR rate is equal to or below the standard-care group's rate.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$190 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $730 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,871 loss on $10,000 · 78.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.